Home
NewsNewsMenopause can usher in a host of disruptive symptoms like hot flashes, night sweats and sleep problems. Hormone therapy promises relief. But many women wonder about taking it. That’s because the treatment, subject of a recent expert panel convened by the Food and Drug Administration, has long been shrouded in uncertainty.
It was once used routinely. But in 2002, research testing one type was stopped early because of concerns about increased risks of breast cancer and blood clots. Concerns lingered even though later studies showed the benefits of today’s hormone therapies outweigh the risks for many women.
“There is still a lot of confusion and a lot of fear,” said Grayson Leverenz, a 50-year-old from Durham, North Carolina, who hesitated to take it but is glad she did.
Others increasingly are also giving hormone therapy a second look. But experts continue to disagree about how to present the treatment’s pros and cons. The FDA-assembled panel stressed the benefits and suggested health warnings be removed from at least some versions — prompting dozens of experts to call for more input before making any changes.
Doctors say hormone therapy is a great option for many, but not all, menopausal women — and it’s important to understand the nuanced reality of these treatments before deciding what’s best.
For the first time, the World Health Organization has officially listed the Ministry of Health, Labor, and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, Health Canada, and the Medicines and Healthcare Products Regulatory Agency (MHRA) of the UK as the new WHO-listed authorities (WLAs), a status that is granted to national authorities that meet the highest international regulatory benchmarks when it comes to medical products.
Fertility is a person’s ability to conceive children. In general, when a woman is unable to get pregnant even after at least one year of unprotected sex, she is considered to have infertility and her doctor will begin evaluating the possible causes.
With the partnership, PatientPoint’s waiting room and exam room screens will feature messaging that promotes MyHealthTeam’s platform, which serves over 27 million patients annually through an expanding network of more than 60 patient communities
In an age where customization is prized as well as friction is the enemy of efficiency, zero-click care – passive patient engagement by way of ambient sensing and IoT in hospitals
Explore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors aExplore the cost of IUI worldwide, comparing prices and factors a
Under the terms of the agreement, Exeltis will acquire exclusive rights to market and distribute Theranexus’ proprietary product across key regions, including the European Union, UK, Latin America, and selected Middle Eastern countries. This collaboration will target both Gaucher and Niemann-Pick type C diseases.
